Boehringer Ingelheim
Metabolic diseases
Site Map
Contact
Home
Health authorities and governments have been alarmed by recent epidemiological data suggesting that metabolic diseases, including obesity, diabetes mellitus type II and dyslipidemia, will grow worldwide by a much greater extent than previously expected. This has been identified as a major health problem not only for industrialised societies but also in, for example, South America, India and China.

Particularly worrisome is the increasing prevalence of obesity in children together with the onset of type II diabetes in young adults. This disturbing fact leads to the forecast that today’s children may have a lower life expectancy than their parent generation. We are therefore putting great efforts on the metabolic disease field with particular focus on diabetes type II, obesity and dyslipidemia.
 
Interesting Links
Metabolic diseases New therapeutic approaches for the treatment of diabetes type II have the potential of delaying or even inhibiting the progression of the disease.

Several research projects even offer the possibility of preventing manifestation of the illness. We were successful in several of our research projects and have achieved promising results in preclinical but also clinical trials.
In obesity there is a great need for new drugs that are more efficacious than the existing ones while providing a high level of patient safety. Research in that area is directed both at a reduction of appetite and food intake as well as increasing the metabolism of energy carriers. We have established state-of-the-art technologies to carefully profile advanced compounds in vitro and in vivo.

Despite efficacious treatment for the lowering of low-density lipoprotein (LDL) cholesterol, 60 % to 70 % of cardiovascular events still cannot be prohibited. The role of low levels of high-density lipoprotein (HDL) cholesterol and malfunction of the reverse cholesterol transport are hence areas of increasing research interest.

We have started several new research projects to address that therapeutic need.
 

Up

 

© 1999 Boehringer Ingelheim GmbH, Germany. All rights reserved. 
Imprint | Terms of use

Last update: 08.04.2008